ContributorsPublishersAdvertisers

Dr. Johnson on the Promise of DS-7300 in SCLC and Other Advanced Solid Tumors

onclive.com
 2021-10-13

Melissa L. Johnson, MD, discusses the promise of DS-7300 in small cell lung cancer and other advanced solid tumors. Melissa L. Johnson, MD, program director, Lung Cancer Research, lead, Solid Tumor Immune Effector Cellular Therapy Program, Sarah...

www.onclive.com

Comments / 0

Comments / 0